Want to see ANGO full AI Analyst Report?
ANGO Stock Chart & Stats
$15.69
$0.07(0.52%)
At close: 4:00 PM EDT
$15.69
$0.07(0.52%)
Day’s Range― - ―
52-Week Range$9.39 - $16.29
Previous Close$13.66
Volume403.10K
Average Volume (3M)842.36K
Market Cap
$496.66M
Enterprise Value$654.58M
Total Cash (Recent Filing)$33.97M
Total Debt (Recent Filing)$10.74M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Jan 07, 2027EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding42,054,450
10 Day Avg. Volume1,400,432
30 Day Avg. Volume842,359
Financial Highlights & Ratios
PEG Ratio-2.06
Price to Book (P/B)2.65
Price to Sales (P/S)1.42
P/FCF Ratio891.83
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue2.01
Enterprise Value/Gross Profit3.61
Enterprise Value/Ebitda-66.31
Forecast
1Y Price Target
$19.00Price Target Upside21.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$337.70M
Bulls Say, Bears Say
Bulls Say
Auryon Growth And Share GainsAuryon’s sustained double-digit growth across hospital and office-based laboratory settings indicates durable adoption and expanding commercial reach. Continued international uptake and share gains can strengthen the MedTech mix, support recurring procedure-related demand, and improve the company’s growth profile over the next several quarters.
MedTech-led Revenue ExpansionThe shift toward faster-growing MedTech products is strategically important because it can raise the company’s growth rate and increase exposure to expanding interventional markets. MedTech’s growing revenue contribution also supports management’s stated plan for continued investment and a more favorable business mix.
Debt-free Balance SheetZero debt and a meaningful cash balance provide financial flexibility while the company invests in product development, clinical programs, and commercial expansion. The absence of interest and refinancing obligations also gives AngioDynamics greater capacity to manage operating volatility and fund its MedTech strategy internally.
Bears Say
Persistent Operating LossesThe continued adjusted-loss outlook shows that revenue growth and improved EBITDA have not yet translated into consistent bottom-line profitability. Until earnings turn sustainably positive, the company remains reliant on further operating leverage and execution, limiting the durability of its financial improvement.
Inconsistent NanoKnife ReimbursementNanoKnife’s expansion depends partly on broader and more predictable reimbursement, so uneven national coverage can slow physician adoption, procedure growth, and disposable utilization. Even with positive decisions in some regions, continued reimbursement work creates an execution and commercialization constraint over the medium term.
Margin Sustainability RisksThe reported margin improvement was partly supported by a non-recurring tariff refund, while management cited manufacturing transition and inflation pressures. With expected margins higher in the first half than the second half, sustaining recent profitability gains may require continued pricing, mix, and cost-control execution.
AngioDynamics News
ANGO FAQ
What was AngioDynamics’s price range in the past 12 months?
AngioDynamics lowest stock price was $9.39 and its highest was $16.29 in the past 12 months.
What is AngioDynamics’s market cap?
AngioDynamics’s market cap is $496.66M.
When is AngioDynamics’s upcoming earnings report date?
AngioDynamics’s upcoming earnings report date is Jan 07, 2027 which is in 77 days.
How were AngioDynamics’s earnings last quarter?
AngioDynamics released its earnings results on Oct 08, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.112 by $0.072.
Is AngioDynamics overvalued?
According to Wall Street analysts AngioDynamics’s price is currently Undervalued.
Does AngioDynamics pay dividends?
AngioDynamics does not currently pay dividends.
What is AngioDynamics’s EPS estimate?
AngioDynamics’s EPS estimate is -0.07.
How many shares outstanding does AngioDynamics have?
AngioDynamics has 42,054,450 shares outstanding.
What happened to AngioDynamics’s price movement after its last earnings report?
AngioDynamics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.112. Following the earnings report the stock price went down -20.86%.
Which hedge fund is a major shareholder of AngioDynamics?
Currently, no hedge funds are holding shares in ANGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AngioDynamics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (21.10% Upside)
$19.00 (21.10% Upside)
Blogger Sentiment
Neutral
ANGO Sentiment 60%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 816.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $344.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.62%
12-Months-Change
Fundamentals
Return on Equity
-19.25%
Trailing 12-Months
Asset Growth
-8.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AngioDynamics
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
ANGO Company Deck
ANGO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call had a strongly positive tone, supported by 6.9% total revenue growth, 13.2% MedTech growth, sustained double-digit Auryon growth, strong AlphaVac and NanoKnife performance, improved profitability, a debt-free balance sheet, and maintained fiscal-year guidance. The principal challenges were the year-over-year AngioVac decline, sequential NanoKnife disposable seasonality, cash usage in Q1, tariff and inflation-related margin factors, an ongoing adjusted loss outlook, and the need for broader NanoKnife reimbursement. Highlights significantly outweighed the lowlights.View all ANGO earnings summariesANGO Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$19.00
▲(21.10% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
InfuSystem Holdings
―
Orasure Technologies
―
Stereotaxis
―
Utah Medical Products
―
Sanara MedTech
―
Ownership Overview
5.63% Insiders
15.62% Mutual Funds
3.67% Other Institutional Investors
62.13% Public Companies and
Individual Investors











